Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Quatera 700 vs. Centurion

NCT: NCT06225362 · COMPLETED

NCT IDNCT06225362
StatusCOMPLETED
Start Date2024-01-10
Completion2025-10-06

Brief Summary

Phacoemulsification is the most common treatment for cataract surgery in the developed countries and over the years it gained importance due to several factors: small incision, surgery performed under topical anesthesia - which reduce injection-related complications - short recovery time, low post operatory induced astigmatism, and low incidence of surgical complications, when compared to the conventional surgeries. The study evaluates 2 different phacoemulsification devices in patients undergoing routine cataract surgery in both eyes.

Frequently Asked Questions

What is Quatera 700 vs. Centurion?

Quatera 700 vs. Centurion is a clinical trial registered under NCT06225362. Current status: COMPLETED.

What is the status of NCT06225362?

The current status of NCT06225362 (Quatera 700 vs. Centurion) is: COMPLETED.

When did Quatera 700 vs. Centurion start?

Quatera 700 vs. Centurion started on 2024-01-10.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.